Deborah Dunsire - Jun 1, 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Director
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Stock symbol
SYRS
Transactions as of
Jun 1, 2023
Transactions value $
$0
Form type
4
Date filed
6/2/2023, 04:23 PM
Previous filing
Sep 19, 2022
Next filing
Jun 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Stock Option (right to buy) Award $0 +6K $0.00 6K Jun 1, 2023 Common Stock 6K $3.70 Direct F1
transaction SYRS Restricted Stock Units Award $0 +4K $0.00 4K Jun 1, 2023 Common Stock 4K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.
F2 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.
F3 These RSUs will vest in their entirety on the earlier to occur of (i) the first anniversary of the date of grant of the award, or (ii) the date of the Company's next Annual Meeting of Stockholders, subject in each case to the director's continued service as a director through the applicable vesting date.